ADLDT: An Opportunity to Expand the National Donor Pool
ADLDT:扩大国家捐助者库的机会
基本信息
- 批准号:7617327
- 负责人:
- 金额:$ 7.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-09-17 至 2009-08-31
- 项目状态:已结题
- 来源:
- 关键词:AbbreviationsAddressAdultChronicClinical ResearchClinical Research ProtocolsComplicationDatabasesDiseaseDonor ExclusionsEnd PointEnrollmentEthnic OriginEvaluationExclusion CriteriaGeneric DrugsGraft SurvivalHealthHealthcareHepatitis C virusInterventionLifeLiverLiver RegenerationLiver diseasesLiving Donor Liver TransplantationLiving DonorsMeasurementModelingNatural HistoryNumbersOrganOrgan TransplantationOutcomeParticipantPatientsPostoperative PeriodProtocols documentationQuality of lifeQuestionnairesRNARateRecoveryRecurrenceResourcesSample SizeScoreSeverity of illnessStagingSurvival AnalysisTechniquesTernTimeTransplant RecipientsTransplantationUnited Network for Organ SharingUpper armVariantViralbasecohorthealth care service utilizationhealth related quality of lifeindexinginstrumentliver transplantationprograms
项目摘要
The overall objective of this proposal is to establish a Clinical Research Consortium to define the outcomes of ALDLT.
We propose the following specific aims to fully evaluate the impact of ALDLT:
1. Core Study: Establish a Donor and Recipient Core Information Database for Adult LDLT and Non-ALDLT Patients
Hypothesis: ALDLT short-term survival outcomes, but not complication rates, are equivalent to whole cadaveric and SLT
transplantation. We and others, achieved excellent short-tern survival outcomes of ALDLT, despite a high rate of recipient
complications, in non-urgent patients. To fully evaluate the benefits of ALDLT, the technique will be applied to both urgent
and non-urgent recipients, and compare its outcomes to three sets of patient cohorts that include: a) whole organ
recipients, b) cadaveric SLT recipients, and c) candidates who ultimately do not receive a transplant. The living donor
section will compare living donors and potential donors who do not undergo donation. Primary endpoints define survival
outcomes and complication rates in donors and recipients at 1, 2 and 3 years posttransplantation. This will elucidate the
efficacy of ALDLT as compared to whole cadaveric, SLT, and control (untransplanted) patients in the entire spectrum of
recipients' status, and determine if ALDLT is justified when compared to the natural history of non-transplanted non-
urgent controls. Secondary endpoints assess the impact of technical variations on postoperative recovery, liver
regeneration postdonation, impact of living donation on the cadaveric donor pool, and defines donor exclusion criteria.
2. Clinical Research Protocol for Recipient Outcome: Determine the impact of ALDLT on Posttransplant HCV Recurrence
in Transplant Recipients Hypothesis: ALDLT may be accompanied by accelerated recurrence of HCV versus whole
cadaveric liver transplantation. Rapid and severe HCV recurrence observed, at our center, in ALDLT recipients compared
to whole organ transplant patients, may offset the benefits of early transplantation with living donors. This protocol
compares the time to histological recurrence of HCV in ALDLT and whole organ graft recipients at 6 months, 1, 2, and 3
years posttransplantation. The effects on patient and graft survival and the correlation between the degree of histological
disease and HCV RNA levels are investigated by our secondary endpoints.
3. Clinical Research Protocol for Donor Outcome: Determine Health-Related Quality of Life Outcomes and Resource
Utilization of Adult Living Donation Hypothesis: HRQL of living donors is impacted in the short-, but not, the long-term and
the HRQL of ALDLT recipients may be enhanced following ALDLT. HRQL in both donors and recipients will be compared
before ALDLT and at 6 and 12 months posttransplantation through generic and disease-specific instruments. Additionally,
health utility index assessments and evaluation of health care resource utilization will be conducted.
该提案的总体目标是建立一个临床研究联盟,以确定ALDLT的结果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rafik MARK GHOBRIAL其他文献
Rafik MARK GHOBRIAL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rafik MARK GHOBRIAL', 18)}}的其他基金
4/4-American Consortium of Early Liver Transplantation-Prospective Alcohol-associated liver disease Cohort Evaluation (ACCELERATE-PACE)
4/4-美国早期肝移植联盟-前瞻性酒精相关性肝病队列评估(ACCELERATE-PACE)
- 批准号:
10711018 - 财政年份:2023
- 资助金额:
$ 7.21万 - 项目类别:
TRANSPLANT IMMUNOMODULATION BY ALLOCHIMERIC MOLECULES
通过异种嵌合分子进行移植免疫调节
- 批准号:
6760900 - 财政年份:2003
- 资助金额:
$ 7.21万 - 项目类别:
TRANSPLANT IMMUNOMODULATION BY ALLOCHIMERIC MOLECULES
通过异种嵌合分子进行移植免疫调节
- 批准号:
6999763 - 财政年份:2003
- 资助金额:
$ 7.21万 - 项目类别:
TRANSPLANT IMMUNOMODULATION BY ALLOCHIMERIC MOLECULES
通过异种嵌合分子进行移植免疫调节
- 批准号:
7156937 - 财政年份:2003
- 资助金额:
$ 7.21万 - 项目类别:
TRANSPLANT IMMUNOMODULATION BY ALLOCHIMERIC MOLECULES
通过异种嵌合分子进行移植免疫调节
- 批准号:
6838746 - 财政年份:2003
- 资助金额:
$ 7.21万 - 项目类别:
TRANSPLANT IMMUNOMODULATION BY ALLOCHIMERIC MOLECULES
通过异种嵌合分子进行移植免疫调节
- 批准号:
6679033 - 财政年份:2003
- 资助金额:
$ 7.21万 - 项目类别:
ADLDT: An Opportunity to Expand the National Donor Pool
ADLDT:扩大国家捐助库的机会
- 批准号:
7276431 - 财政年份:2002
- 资助金额:
$ 7.21万 - 项目类别:
ADLDT: An Opportunity to Expand the National Donor Pool
ADLDT:扩大国家捐助库的机会
- 批准号:
6660317 - 财政年份:2002
- 资助金额:
$ 7.21万 - 项目类别:
ADLDT: An Opportunity to Expand the National Donor Pool
ADLDT:扩大国家捐助库的机会
- 批准号:
7120588 - 财政年份:2002
- 资助金额:
$ 7.21万 - 项目类别:
ADLDT: An Opportunity to Expand the National Donor Pool
ADLDT:扩大国家捐助库的机会
- 批准号:
6945885 - 财政年份:2002
- 资助金额:
$ 7.21万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 7.21万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 7.21万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 7.21万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 7.21万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 7.21万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 7.21万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 7.21万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 7.21万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 7.21万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 7.21万 - 项目类别:
Research Grant